-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5

Benzinga·08/18/2026 12:03:50
Listen to the news
Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.